RGD Reference Report - Exploration of the Correlations Between Interferon-gamma in Patient Serum and HEPACAM in Bladder Transitional Cell Carcinoma, and the Interferon-gamma Mechanism Inhibiting BIU-87 Proliferation. - Rat Genome Database

Send us a Message



Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   

Exploration of the Correlations Between Interferon-gamma in Patient Serum and HEPACAM in Bladder Transitional Cell Carcinoma, and the Interferon-gamma Mechanism Inhibiting BIU-87 Proliferation.

Authors: Xu, B  He, Y  Wu, X  Luo, C  Liu, A  Zhang, J 
Citation: Xu B, etal., J Urol. 2012 Aug 17.
RGD ID: 6893349
Pubmed: PMID:22906662   (View Abstract at PubMed)
DOI: DOI:10.1016/j.juro.2012.06.005   (Journal Full-text)

PURPOSE: Interferon-gamma inhibits cancer cell proliferation and induces re-expression of different tumor suppressor genes. As a candidate, HEPACAM is almost lost in bladder transitional cell carcinoma. To our knowledge whether interferon-gamma inhibits BIU-87 proliferation and re-expresses HEPACAM mRNA is still unknown. Thus, we probed the mechanism and examined the correlations between interferon-gamma in patient serum and HEPACAM in bladder transitional cell carcinoma. MATERIALS AND METHODS: Using enzyme-linked immunosorbent assay we measured serum interferon-gamma in 27 men and 6 women, and 15 volunteers. Disease was Ta-T1 in 12 patients, T2-T4 in 21, low grade in 25, high grade in 8, primary in 13 and recurrent in 20. A total of 33 cancer and 26 adjacent tissues were examined by immunohistochemistry to detect HEPACAM protein and ensure the position. Under interferon-gamma stimulation we detected BIU-87 proliferation by MTT assay. Cell cycles were examined by flow cytometry. HEPACAM mRNA expression was determined by reverse transcription-polymerase chain reaction. Western blot was used to detect p21(WAF1). RESULTS: Interferon-gamma was remarkably low in patients with bladder transitional cell carcinoma vs volunteers (p <0.01). HEPACAM protein was highly expressed in adjacent tissue, mainly at the cytomembrane, but it was almost absent in bladder transitional cell carcinoma (p <0.01). The interferon-gamma decrease in the serum of patients with bladder transitional cell carcinoma and the low HEPACAM expression in tumors correlated linearly (r = 0.899, p <0.01). In vitro interferon-gamma inhibited BIU-87 proliferation (p <0.01) and slightly re-expressed HEPACAM mRNA (p <0.05). The cell cycle was arrested at G(0)/G(1) and p21(WAF1) was concurrently increased in response to interferon-gamma (p <0.01). CONCLUSIONS: Results suggest an important connection between HEPACAM and interferon-gamma, which may inhibit BIU-87 proliferation through HEPACAM re-expression and p21(WAF1) up-regulation to arrest cells at the G(0)/G(1) phase.

RGD Manual Disease Annotations    Click to see Annotation Detail View
TermQualifierEvidenceWithReferenceNotesSourceOriginal Reference(s)
urinary bladder cancer  IEP 6893349protein:decreased expression:serumRGD 
urinary bladder cancer  ISOIFNG (Homo sapiens)6893349; 6893349protein:decreased expression:serumRGD 

Objects Annotated

Genes (Rattus norvegicus)
Ifng  (interferon gamma)

Genes (Mus musculus)
Ifng  (interferon gamma)

Genes (Homo sapiens)
IFNG  (interferon gamma)


Additional Information